Crizotinib

Search with Google Search with Bing

Information
Drug Name
Crizotinib
Description
Entry(CIViC)
107
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
lung adenocarcinoma NTRK1 NTRK1 FUSIONS NTRK1 NTRK1 FUSIONS D Predictive Supports Sensitivity/Response Somatic 3 24162815 Detail
lung non-small cell carcinoma ROS1 REARRANGEMENT ROS1 REARRANGEMENT B Predictive Supports Sensitivity/Response Somatic 3 25667280 Detail
lung non-small cell carcinoma MET EXON 14 MUTATION + AMPLIFICATION
( ENST00000318493.11 ) MET EXON 14 MUTATION + AMPLIFICATION
( ENST00000318493.11 ) 		C Predictive Supports Sensitivity/Response Somatic 3 26729443 Detail
lung adenocarcinoma ROS1 CD74-ROS1 G2032R C Predictive Supports Resistance Somatic 4 23724914 Detail
lung adenocarcinoma MET EXON 14 SKIPPING MUTATION MET EXON 14 SKIPPING MUTATION C Predictive Supports Sensitivity/Response Somatic 3 26729443 Detail
lung non-small cell carcinoma ALK ALK FUSIONS ALK ALK FUSIONS A Predictive Supports Sensitivity/Response Somatic 5 20979469 Detail
lung non-small cell carcinoma ALK EML4-ALK E20;A20 C Predictive Supports Sensitivity/Response Somatic 2 20979469 Detail
lung non-small cell carcinoma ALK EML4-ALK E2;A20 E Predictive Supports Sensitivity/Response Somatic 4 18927303 Detail
lung non-small cell carcinoma ALK EML4-ALK E6;A20 C Predictive Supports Sensitivity/Response Somatic 4 20979469 Detail
lung non-small cell carcinoma ALK EML4-ALK E20;A20 D Predictive Supports Sensitivity/Response Somatic 2 22912387 Detail
lung non-small cell carcinoma ALK EML4-ALK E6;A20 D Predictive Does Not Support Sensitivity/Response Somatic 2 22912387 Detail
lung non-small cell carcinoma ALK ALK FUSIONS ALK ALK FUSIONS A Predictive Supports Sensitivity/Response Somatic 5 23724913 Detail
lung non-small cell carcinoma ALK ALK FUSIONS ALK ALK FUSIONS A Predictive Supports Sensitivity/Response Somatic 5 25470694 Detail
lung non-small cell carcinoma ALK ALK FUSIONS ALK ALK FUSIONS B Predictive Supports Sensitivity/Response Somatic 4 24478318 Detail
lung non-small cell carcinoma ALK ALK FUSIONS ALK ALK FUSIONS B Predictive Supports Sensitivity/Response Somatic 4 27022118 Detail
lung non-small cell carcinoma ALK EML4-ALK D Predictive Supports Sensitivity/Response Somatic 4 21258415 Detail
lung non-small cell carcinoma ALK EML4-ALK E20;A20 D Predictive Supports Sensitivity/Response Somatic 2 22912387 Detail
lung non-small cell carcinoma ALK EML4-ALK D Predictive Supports Sensitivity/Response Somatic 2 22912387 Detail
lung non-small cell carcinoma ALK EML4-ALK C Predictive Supports Sensitivity/Response Somatic 4 20979469 Detail
anaplastic large cell lymphoma ALK NPM-ALK D Predictive Supports Sensitivity/Response Somatic 5 18089725 Detail
anaplastic large cell lymphoma ALK ALK FUSIONS ALK ALK FUSIONS C Predictive Supports Sensitivity/Response Somatic 4 21345110 Detail
anaplastic large cell lymphoma ALK NPM-ALK B Predictive Supports Sensitivity/Response Somatic 4 23598171 Detail
inflammatory myofibroblastic tumor ALK ALK FUSIONS ALK ALK FUSIONS B Predictive Supports Sensitivity/Response Somatic 3 23598171 Detail
inflammatory myofibroblastic tumor ALK RANBP2-ALK C Predictive Supports Sensitivity/Response Somatic 4 20979472 Detail
cancer ALK EML4-ALK E20;A20 C Predictive Supports Sensitivity/Response Somatic 3 25408655 Detail
neuroblastoma ALK p.Phe1174Leu (p.F1174L)
( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) ALK p.Phe1174Leu (p.F1174L)
( ENST00000618119.4, ENST00000642122.1, ENST00000389048.8 ) 		D Predictive Supports Resistance Somatic 3 22072639 Detail
lung non-small cell carcinoma ROS1 CD74-ROS1 G2032R D Predictive Supports Resistance Somatic 3 26372962 Detail
lung non-small cell carcinoma ROS1 CD74-ROS1 L2026M D Predictive Supports Resistance Somatic 2 25733882 Detail
lung non-small cell carcinoma ROS1 CD74-ROS1 G2032R C Predictive Supports Resistance Somatic 3 25688157 Detail
lung non-small cell carcinoma ROS1 CD74-ROS1 L2155S D Predictive Supports Resistance Somatic 3 25688157 Detail
lung non-small cell carcinoma ROS1 CD74-ROS1 L2026M D Predictive Supports Resistance Somatic 2 25688157 Detail
lung non-small cell carcinoma ROS1 CD74-ROS1 G2101A D Predictive Supports Resistance Somatic 2 25688157 Detail
diffuse large B-cell lymphoma ALK ALK FUSIONS ALK ALK FUSIONS C Predictive Supports Sensitivity/Response Somatic 2 24330038 Detail
diffuse large B-cell lymphoma ALK CLTC-ALK C Predictive Supports Sensitivity/Response Somatic 3 26221234 Detail
neuroblastoma ALK p.Arg1275Gln (p.R1275Q)
( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) ALK p.Arg1275Gln (p.R1275Q)
( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) 		C Predictive Supports Sensitivity/Response Rare Germline 2 23598171 Detail
neuroblastoma ALK p.Arg1275Gln (p.R1275Q)
( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) ALK p.Arg1275Gln (p.R1275Q)
( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) 		C Predictive Supports Sensitivity/Response Somatic 2 23598171 Detail
neuroblastoma ALK p.Phe1174Leu (p.F1174L)
( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) ALK p.Phe1174Leu (p.F1174L)
( ENST00000618119.4, ENST00000642122.1, ENST00000389048.8 ) 		C Predictive Does Not Support Sensitivity/Response Somatic 3 23598171 Detail
lung non-small cell carcinoma ALK p.Ile1171Thr (p.I1171T) ALK p.Ile1171Thr (p.I1171T) D Predictive Supports Resistance Somatic 3 25228534 Detail
lung non-small cell carcinoma ALK EML4-ALK V1180L D Predictive Supports Resistance Somatic 2 25228534 Detail
colorectal adenocarcinoma ROS1 REARRANGEMENT ROS1 REARRANGEMENT E Predictive Supports Sensitivity/Response Somatic 2 24296758 Detail
neuroblastoma ALK p.Phe1245Cys (p.F1245C)
( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) ALK p.Phe1245Cys (p.F1245C)
( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) 		C Predictive Supports Resistance Somatic 3 23598171 Detail
colorectal adenocarcinoma ALK ALK FUSIONS ALK ALK FUSIONS E Predictive Supports Sensitivity/Response Somatic 1 19737969 Detail
breast cancer ALK ALK FUSIONS ALK ALK FUSIONS E Predictive Supports Sensitivity/Response Somatic 1 19737969 Detail
cancer ALK p.Phe1245Cys (p.F1245C) ALK p.Phe1245Cys (p.F1245C) D Predictive Supports Resistance Somatic 2 22034911 Detail
lung non-small cell carcinoma ALK p.Phe1245Cys (p.F1245C) ALK p.Phe1245Cys (p.F1245C) C Predictive Supports Resistance Somatic 2 26775591 Detail
lung non-small cell carcinoma ALK EML4-ALK C1156Y D Predictive Supports Resistance Somatic 4 24675041 Detail
cancer ALK NPM-ALK D Predictive Supports Sensitivity/Response Somatic 2 25727400 Detail
lung adenocarcinoma ALK p.Gly1202Arg (p.G1202R) ALK p.Gly1202Arg (p.G1202R) C Predictive Supports Resistance Somatic 3 22277784 Detail
lung non-small cell carcinoma ALK ALK FUSIONS ALK ALK FUSIONS B Predictive Supports Sensitivity/Response Somatic 3 21933749 Detail
neuroblastoma ALK p.Arg1275Gln (p.R1275Q)
( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) ALK p.Arg1275Gln (p.R1275Q)
( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) 		D Predictive Supports Sensitivity/Response Somatic 3 22072639 Detail
bronchiolo-alveolar adenocarcinoma ROS1 REARRANGEMENT ROS1 REARRANGEMENT C Predictive Supports Sensitivity/Response Somatic 3 22215748 Detail
inflammatory myofibroblastic tumor ROS1 TFG-ROS1 C Predictive Supports Sensitivity/Response Somatic 3 24875859 Detail
lung non-small cell carcinoma ALK HIP1-ALK I1171N C Predictive Supports Resistance Somatic 2 25393796 Detail
lung non-small cell carcinoma ALK EML4-ALK I1171S C Predictive Supports Resistance Somatic 2 25393796 Detail
glioblastoma MET AMPLIFICATION
( ENST00000318493.11 ) MET AMPLIFICATION
( ENST00000318493.11 ) 		C Predictive Supports Sensitivity/Response Somatic 3 22162573 Detail
lung non-small cell carcinoma MET AMPLIFICATION
( ENST00000318493.11 ) MET AMPLIFICATION
( ENST00000318493.11 ) 		D Predictive Supports Sensitivity/Response Somatic 4 21716144 Detail
lung non-small cell carcinoma ALK ALK FUSIONS ALK ALK FUSIONS B Predictive Supports Sensitivity/Response Somatic 3 26466010 Detail
uveal melanoma MET OVEREXPRESSION
( ENST00000318493.11 ) MET OVEREXPRESSION
( ENST00000318493.11 ) 		D Predictive Supports Sensitivity/Response N/A 1 24140933 Detail
colorectal cancer MET AMPLIFICATION
( ENST00000318493.11 ) MET AMPLIFICATION
( ENST00000318493.11 ) 		C Predictive Supports Sensitivity/Response N/A 4 27325282 Detail
lung adenocarcinoma MET EXON 14 SKIPPING MUTATION MET EXON 14 SKIPPING MUTATION C Predictive Supports Sensitivity/Response Somatic 2 26845194 Detail
lung non-small cell carcinoma MET p.Asp1246Asn (p.D1246N)
( ENST00000318493.11, ENST00000397752.8 ) MET p.Asp1246Asn (p.D1246N)
( ENST00000318493.11, ENST00000397752.8 ) 		C Predictive Supports Resistance Somatic 2 27343442 Detail
lung adenocarcinoma ROS1 REARRANGEMENT ROS1 REARRANGEMENT C Predictive Supports Sensitivity/Response Somatic 3 25922291 Detail
lung adenocarcinoma ALK ALK FUSIONS ALK ALK FUSIONS C Predictive Supports Sensitivity/Response Somatic 3 25922291 Detail
lung adenocarcinoma MET AMPLIFICATION
( ENST00000318493.11 ) MET AMPLIFICATION
( ENST00000318493.11 ) 		C Predictive Supports Sensitivity/Response Somatic 3 25922291 Detail
lung non-small cell carcinoma MET AMPLIFICATION
( ENST00000318493.11 ) MET AMPLIFICATION
( ENST00000318493.11 ) 		C Predictive Supports Sensitivity/Response N/A 2 27664533 Detail
cancer MET AMPLIFICATION
( ENST00000318493.11 ) MET AMPLIFICATION
( ENST00000318493.11 ) 		C Predictive Supports Sensitivity/Response N/A 3 25232318 Detail
cancer KRAS p.Gly12Val (p.G12V)
( ENST00000688940.1, ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000693229.1 ) KRAS p.Gly12Val (p.G12V)
( ENST00000693229.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1 ) 		C Predictive Does Not Support Resistance Somatic 2 25232318 Detail
salivary gland carcinoma NTRK3 ETV6-NTRK3 C Predictive Does Not Support Sensitivity/Response Somatic 2 26884591 Detail
skin melanoma ALK ALTERNATIVE TRANSCRIPT (ATI) ALK ALTERNATIVE TRANSCRIPT (ATI) C Predictive Supports Sensitivity/Response N/A 4 26444240 Detail
colorectal cancer MET AMPLIFICATION
( ENST00000318493.11 ) MET AMPLIFICATION
( ENST00000318493.11 ) 		D Predictive Supports Sensitivity/Response Somatic 3 23729478 Detail
lung non-small cell carcinoma ALK EML4-ALK C1156Y–L1196M C Predictive Supports Resistance Somatic 4 20979473 Detail
lung non-small cell carcinoma ALK EML4-ALK L1196M B Predictive Supports Resistance Somatic 4 20979473 Detail
lung non-small cell carcinoma ALK EML4-ALK B Predictive Supports Sensitivity/Response Somatic 4 20979473 Detail
lung adenocarcinoma ROS1 p.Gly2032Arg (p.G2032R)
( ENST00000368507.8, ENST00000368508.7 ) ROS1 p.Gly2032Arg (p.G2032R)
( ENST00000368507.8, ENST00000368508.7 ) 		C Predictive Supports Resistance Somatic 1 23724914 Detail
inflammatory myofibroblastic tumor ALK p.Phe1174Leu (p.F1174L)
( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) ALK p.Phe1174Leu (p.F1174L)
( ENST00000618119.4, ENST00000642122.1, ENST00000389048.8 ) 		D Predictive Supports Resistance Somatic 3 21030459 Detail
lung non-small cell carcinoma ALK p.Phe1174Leu (p.F1174L)
( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) ALK p.Phe1174Leu (p.F1174L)
( ENST00000618119.4, ENST00000642122.1, ENST00000389048.8 ) 		D Predictive Supports Resistance Somatic 3 21030459 Detail
neuroblastoma ALK p.Phe1174Leu (p.F1174L)
( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) ALK p.Phe1174Leu (p.F1174L)
( ENST00000618119.4, ENST00000642122.1, ENST00000389048.8 ) 		D Predictive Supports Sensitivity/Response Somatic 3 21948233 Detail
lung non-small cell carcinoma EGFR p.Leu858Arg (p.L858R)
( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R)
( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) 		C Predictive Supports Resistance Somatic 22235099 Detail
lung non-small cell carcinoma ALK EML4-ALK AMPLIFICATION D Predictive Supports Resistance Somatic 3 22277784 Detail
lung non-small cell carcinoma ALK p.Gly1202Arg (p.G1202R) ALK p.Gly1202Arg (p.G1202R) D Predictive Supports Resistance Somatic 4 22277784 Detail
lung non-small cell carcinoma ALK EML4-ALK L1196M D Predictive Supports Resistance Somatic 4 22277784 Detail
lung non-small cell carcinoma ALK EML4-ALK S1206Y D Predictive Supports Resistance Somatic 4 22277784 Detail
lung non-small cell carcinoma ALK EML4-ALK T1151INST C Predictive Supports Resistance Somatic 4 22277784 Detail
lung adenocarcinoma MET EXON 14 SKIPPING MUTATION MET EXON 14 SKIPPING MUTATION C Predictive Supports Sensitivity/Response Somatic 1 25769807 Detail
lung non-small cell carcinoma ALK ALK FUSIONS ALK ALK FUSIONS B Predictive Supports Sensitivity/Response Somatic 5 28586279 Detail
Anaplastic thyroid carcinoma ALK ALK FUSIONS ALK ALK FUSIONS C Predictive Supports Sensitivity/Response Somatic 3 24687827 Detail
vagina sarcoma ALK ALK FUSIONS ALK ALK FUSIONS C Predictive Supports Sensitivity/Response Somatic 2 26942346 Detail
epithelioid inflammatory myofibroblastic sarcoma ALK ALK FUSIONS ALK ALK FUSIONS C Predictive Supports Sensitivity/Response Somatic 2 25028698 Detail
lung non-small cell carcinoma ROS1 REARRANGEMENT ROS1 REARRANGEMENT B Predictive Supports Sensitivity/Response Somatic 4 25264305 Detail
lung non-small cell carcinoma MET AMPLIFICATION
( ENST00000318493.11 ) MET AMPLIFICATION
( ENST00000318493.11 ) 		C Predictive Supports Sensitivity/Response Somatic 3 21623265 Detail
cancer MET EXON 14 SKIPPING MUTATION MET EXON 14 SKIPPING MUTATION D Predictive Supports Sensitivity/Response Somatic 3 26547802 Detail
head and neck cancer MET R1004G MET R1004G C Predictive Supports Sensitivity/Response Somatic 3 31391294 Detail
lung non-small cell carcinoma ALK EML4-ALK L1152R C Predictive Supports Resistance Somatic 4 21791641 Detail
lung non-small cell carcinoma ALK EML4-ALK G1269A C Predictive Supports Resistance Somatic 4 22235099 Detail
lung non-small cell carcinoma MET EXON 14 SKIPPING MUTATION MET EXON 14 SKIPPING MUTATION B Predictive Supports Sensitivity/Response Somatic 1 Detail
lung non-small cell carcinoma MET EXON 14 SKIPPING MUTATION MET EXON 14 SKIPPING MUTATION C Predictive Supports Sensitivity/Response Somatic 2 26892698 Detail
lung non-small cell carcinoma ALK EML4-ALK G1269A C Predictive Supports Resistance Somatic 3 23344087 Detail
lung non-small cell carcinoma ALK EML4-ALK AMPLIFICATION D Predictive Supports Resistance Somatic 3 22235099 Detail
lung non-small cell carcinoma ALK EML4-ALK AMPLIFICATION C Predictive Supports Resistance Somatic 2 23344087 Detail
histiocytic and dendritic cell cancer MET EXON 14 SKIPPING MUTATION MET EXON 14 SKIPPING MUTATION C Predictive Supports Sensitivity/Response Somatic 3 25971938 Detail
lung non-small cell carcinoma AREG EXPRESSION AREG EXPRESSION D Predictive Supports Resistance N/A 3 21791641 Detail
lung non-small cell carcinoma AREG EXPRESSION AREG EXPRESSION B Predictive Supports Resistance N/A 2 23344087 Detail
lung adenocarcinoma MET EXON 14 SKIPPING MUTATION MET EXON 14 SKIPPING MUTATION C Predictive Supports Sensitivity/Response Somatic 3 25971939 Detail
lung adenocarcinoma MET AMPLIFICATION
( ENST00000318493.11 ) MET AMPLIFICATION
( ENST00000318493.11 ) 		C Predictive Supports Sensitivity/Response Somatic 2 26724472 Detail
lung non-small cell carcinoma ALK EML4-ALK C1156Y C Predictive Supports Resistance Somatic 3 26698910 Detail
lung non-small cell carcinoma ALK EML4-ALK C1156Y–L1198F C Predictive Supports Sensitivity/Response Somatic 4 26698910 Detail
lung squamous cell carcinoma MET AMPLIFICATION
( ENST00000318493.11 ) MET AMPLIFICATION
( ENST00000318493.11 ) 		C Predictive Supports Sensitivity/Response Somatic 2 24192513 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
Two patients were found to harbor gene fusions mai... NTRK1 NTRK1 NTRK1 FUSIONS NTRK1 NTRK1 FUSIONS Sensitivity true CIViC Evidence detail
In a retrospective study, 30 patients were evaluat... ROS1 ROS1 REARRANGEMENT ROS1 REARRANGEMENT Sensitivity true CIViC Evidence detail
64-year old female (non-smoker) was diagnosed with... MET MET EXON 14 MUTATION + AMPLIFICATION
( ENST00000318493.11 ) MET EXON 14 MUTATION + AMPLIFICATION
( ENST00000318493.11 ) 		Sensitivity true CIViC Evidence detail
Resistance to crizotinib developed in a patient wi... ROS1 ROS1 CD74-ROS1 G2032R Resitance or Non-Reponse true CIViC Evidence detail
A single patient with a MET c.3028G>A (splice dono... MET MET EXON 14 SKIPPING MUTATION MET EXON 14 SKIPPING MUTATION Sensitivity true CIViC Evidence detail
In the Phase I study PROFILE 1001 (NCT00585195), a... ALK ALK ALK FUSIONS ALK ALK FUSIONS Sensitivity true CIViC Evidence detail
In the PROFILE 1001 study, from 31 NSCLC tumors po... ALK ALK EML4-ALK E20;A20 Sensitivity true CIViC Evidence detail
Multiplex RT-PCR to detect in-frame fusions of EML... ALK ALK EML4-ALK E2;A20 Sensitivity true CIViC Evidence detail
In a set of 31 patients with NSCLC, RT-PCR was per... ALK ALK EML4-ALK E6;A20 Sensitivity true CIViC Evidence detail
EML4-ALK variants v1 (E13;A20), v2 (E20;A20), v3a ... ALK ALK EML4-ALK E20;A20 Sensitivity true CIViC Evidence detail
Ba/F3 cells transduced with EML4-ALK variants v1 (... ALK ALK EML4-ALK E6;A20 Sensitivity false CIViC Evidence detail
This two arm Phase III study named PROFILE 1007 (N... ALK ALK ALK FUSIONS ALK ALK FUSIONS Sensitivity true CIViC Evidence detail
This phase 3 trial named PROFILE 1014 (NCT01154140... ALK ALK ALK FUSIONS ALK ALK FUSIONS Sensitivity true CIViC Evidence detail
This retrospective study of patients from the PROF... ALK ALK ALK FUSIONS ALK ALK FUSIONS Sensitivity true CIViC Evidence detail
This prospective Phase III study named Profile 101... ALK ALK ALK FUSIONS ALK ALK FUSIONS Sensitivity true CIViC Evidence detail
In preclinical work using H3122 NSCLC cells which ... ALK ALK EML4-ALK Sensitivity true CIViC Evidence detail
EML4-ALK fusions occur in 2-7% of lung adenocarcin... ALK ALK EML4-ALK E20;A20 Sensitivity true CIViC Evidence detail
Transduction of Ba/F3 cells with EML4-ALK variant ... ALK ALK EML4-ALK Sensitivity true CIViC Evidence detail
In the PROFILE 1001 study of crizotinib in 82 pati... ALK ALK EML4-ALK Sensitivity true CIViC Evidence detail
NPM-ALK in anaplastic large cell lymphoma (ALCL) w... ALK ALK NPM-ALK Sensitivity true CIViC Evidence detail
Crizotinib at 250mg daily was given to two patient... ALK ALK ALK FUSIONS ALK ALK FUSIONS Sensitivity true CIViC Evidence detail
In the second part of this Phase I study NCT009397... ALK ALK NPM-ALK Sensitivity true CIViC Evidence detail
As part of a phase 1 dose-escalation trial (NCT009... ALK ALK ALK FUSIONS ALK ALK FUSIONS Sensitivity true CIViC Evidence detail
ALK-rearrangements are seen in 50% of inflammatory... ALK ALK RANBP2-ALK Sensitivity true CIViC Evidence detail
This case study presented a 53-year-old never-smok... ALK ALK EML4-ALK E20;A20 Sensitivity true CIViC Evidence detail
Cells lines expressing ALK harboring the F1174L mu... ALK ALK p.Phe1174Leu (p.F1174L)
( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) ALK p.Phe1174Leu (p.F1174L)
( ENST00000618119.4, ENST00000642122.1, ENST00000389048.8 ) 		Resitance or Non-Reponse true CIViC Evidence detail
Preclinical study analyzing the efficacy of dual R... ROS1 ROS1 CD74-ROS1 G2032R Resitance or Non-Reponse true CIViC Evidence detail
Preclinical study of PF-06463922 in NSCLC in-vitro... ROS1 ROS1 CD74-ROS1 L2026M Resitance or Non-Reponse true CIViC Evidence detail
ROS1 kinase domain mutations were assessed in two ... ROS1 ROS1 CD74-ROS1 G2032R Resitance or Non-Reponse true CIViC Evidence detail
The L2155S mutation in ROS1 was identified in the ... ROS1 ROS1 CD74-ROS1 L2155S Resitance or Non-Reponse true CIViC Evidence detail
Ba/F3 cells expressing CD74–ROS1 L2026M mutation s... ROS1 ROS1 CD74-ROS1 L2026M Resitance or Non-Reponse true CIViC Evidence detail
Ba/F3 cells expressing CD74–ROS1 G2101A showed res... ROS1 ROS1 CD74-ROS1 G2101A Resitance or Non-Reponse true CIViC Evidence detail
A 27 year old female patient with advanced-stage I... ALK ALK ALK FUSIONS ALK ALK FUSIONS Sensitivity true CIViC Evidence detail
A 21 year old male presented with lymphadenopathy ... ALK ALK CLTC-ALK Sensitivity true CIViC Evidence detail
This Phase I study of crizotinib involved a cohort... ALK ALK p.Arg1275Gln (p.R1275Q)
( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) ALK p.Arg1275Gln (p.R1275Q)
( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) 		Sensitivity true CIViC Evidence detail
A cohort of pediatric neuroblastoma patients ages ... ALK ALK p.Arg1275Gln (p.R1275Q)
( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) ALK p.Arg1275Gln (p.R1275Q)
( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) 		Sensitivity true CIViC Evidence detail
In a Phase I trial (NCT00939770) of the drug crizo... ALK ALK p.Phe1174Leu (p.F1174L)
( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) ALK p.Phe1174Leu (p.F1174L)
( ENST00000618119.4, ENST00000642122.1, ENST00000389048.8 ) 		Sensitivity false CIViC Evidence detail
The MGH056-1 cell line was derived from a patient ... ALK ALK p.Ile1171Thr (p.I1171T) ALK p.Ile1171Thr (p.I1171T) Resitance or Non-Reponse true CIViC Evidence detail
The alectinib resistant cell line H3122 CHR-A1 was... ALK ALK EML4-ALK V1180L Resitance or Non-Reponse true CIViC Evidence detail
A tissue microarray of 268 patients with histologi... ROS1 ROS1 REARRANGEMENT ROS1 REARRANGEMENT Sensitivity true CIViC Evidence detail
A participant in Children's Oncology Group (COG) s... ALK ALK p.Phe1245Cys (p.F1245C)
( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) ALK p.Phe1245Cys (p.F1245C)
( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
26 colorectal adenocarcinoma samples were run on A... ALK ALK ALK FUSIONS ALK ALK FUSIONS Sensitivity true CIViC Evidence detail
84 breast cancer samples acquired from commercial ... ALK ALK ALK FUSIONS ALK ALK FUSIONS Sensitivity true CIViC Evidence detail
A Ba/F3 cell line expressing EML4-ALK variant 1 wa... ALK ALK p.Phe1245Cys (p.F1245C) ALK p.Phe1245Cys (p.F1245C) Resitance or Non-Reponse true CIViC Evidence detail
A 52 year old with a non-smoking history was diagn... ALK ALK p.Phe1245Cys (p.F1245C) ALK p.Phe1245Cys (p.F1245C) Resitance or Non-Reponse true CIViC Evidence detail
EML4-ALK variant 3 containing NSCLC cell line H222... ALK ALK EML4-ALK C1156Y Resitance or Non-Reponse true CIViC Evidence detail
In Ba/F3 cells, crizotinib sensitivty of the NPM-A... ALK ALK NPM-ALK Sensitivity true CIViC Evidence detail
A patient with ALK-rearranged lung adenocarcinoma ... ALK ALK p.Gly1202Arg (p.G1202R) ALK p.Gly1202Arg (p.G1202R) Resitance or Non-Reponse true CIViC Evidence detail
In a retrospective study comparing survival outcom... ALK ALK ALK FUSIONS ALK ALK FUSIONS Sensitivity true CIViC Evidence detail
Cells lines expressing ALK harboring the F1174L mu... ALK ALK p.Arg1275Gln (p.R1275Q)
( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) ALK p.Arg1275Gln (p.R1275Q)
( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) 		Sensitivity true CIViC Evidence detail
Study describes a 31-year old male, never-smoker p... ROS1 ROS1 REARRANGEMENT ROS1 REARRANGEMENT Sensitivity true CIViC Evidence detail
Case report of a pediatric patient with treatment-... ROS1 ROS1 TFG-ROS1 Sensitivity true CIViC Evidence detail
Case study describes a female (age 58) never-smoke... ALK ALK HIP1-ALK I1171N Resitance or Non-Reponse true CIViC Evidence detail
Case study describes a caucasian male (age 38) nev... ALK ALK EML4-ALK I1171S Resitance or Non-Reponse true CIViC Evidence detail
A 62 year old female was diagnosed with glioblasto... MET MET AMPLIFICATION
( ENST00000318493.11 ) MET AMPLIFICATION
( ENST00000318493.11 ) 		Sensitivity true CIViC Evidence detail
2 MET amplified NSCLC cell lines (EBC-1 and H1993)... MET MET AMPLIFICATION
( ENST00000318493.11 ) MET AMPLIFICATION
( ENST00000318493.11 ) 		Sensitivity true CIViC Evidence detail
A phase-3 clinical trial evaluated 347 patients wi... ALK ALK ALK FUSIONS ALK ALK FUSIONS Sensitivity true CIViC Evidence detail
c-MET and ligand HGF were expressed by 6 uveal mel... MET MET OVEREXPRESSION
( ENST00000318493.11 ) MET OVEREXPRESSION
( ENST00000318493.11 ) 		Sensitivity true CIViC Evidence detail
Case report of a patient with BRAF V600E mutant me... MET MET AMPLIFICATION
( ENST00000318493.11 ) MET AMPLIFICATION
( ENST00000318493.11 ) 		Sensitivity true CIViC Evidence detail
Case report of a patient with lung adenocarcinoma ... MET MET EXON 14 SKIPPING MUTATION MET EXON 14 SKIPPING MUTATION Sensitivity true CIViC Evidence detail
Case report of a patient with NSCLC harboring a ME... MET MET p.Asp1246Asn (p.D1246N)
( ENST00000318493.11, ENST00000397752.8 ) MET p.Asp1246Asn (p.D1246N)
( ENST00000318493.11, ENST00000397752.8 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In an evaluation of a patient and never smoker wit... ROS1 ROS1 REARRANGEMENT ROS1 REARRANGEMENT Sensitivity true CIViC Evidence detail
In an evaluation of a patient with crizotinib-sens... ALK ALK ALK FUSIONS ALK ALK FUSIONS Sensitivity true CIViC Evidence detail
In an evaluation of a patient with crizotinib-sens... MET MET AMPLIFICATION
( ENST00000318493.11 ) MET AMPLIFICATION
( ENST00000318493.11 ) 		Sensitivity true CIViC Evidence detail
Case report of two patients with MET amplification... MET MET AMPLIFICATION
( ENST00000318493.11 ) MET AMPLIFICATION
( ENST00000318493.11 ) 		Sensitivity true CIViC Evidence detail
Case report of a 59-year-old white female patient ... MET MET AMPLIFICATION
( ENST00000318493.11 ) MET AMPLIFICATION
( ENST00000318493.11 ) 		Sensitivity true CIViC Evidence detail
Case report of a 59-year-old white female patient ... KRAS KRAS p.Gly12Val (p.G12V)
( ENST00000688940.1, ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000693229.1 ) KRAS p.Gly12Val (p.G12V)
( ENST00000693229.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1 ) 		Resitance or Non-Reponse false CIViC Evidence detail
Case report of a patient with mammary analogue sec... NTRK3 NTRK3 ETV6-NTRK3 Sensitivity false CIViC Evidence detail
Expression of an alternative ALK transcript (ATI),... ALK ALK ALTERNATIVE TRANSCRIPT (ATI) ALK ALTERNATIVE TRANSCRIPT (ATI) Sensitivity true CIViC Evidence detail
Functional studies show that MET activation confer... MET MET AMPLIFICATION
( ENST00000318493.11 ) MET AMPLIFICATION
( ENST00000318493.11 ) 		Sensitivity true CIViC Evidence detail
A 28 year old patient with T4N3M1 stage lung adeno... ALK ALK EML4-ALK C1156Y–L1196M Resitance or Non-Reponse true CIViC Evidence detail
In patients with non-small cell lung cancer harbor... ALK ALK EML4-ALK L1196M Resitance or Non-Reponse true CIViC Evidence detail
In patients with non-small cell lung cancer harbor... ALK ALK EML4-ALK Sensitivity true CIViC Evidence detail
Resistance to crizotinib developed in a patient wi... ROS1 ROS1 p.Gly2032Arg (p.G2032R)
( ENST00000368507.8, ENST00000368508.7 ) ROS1 p.Gly2032Arg (p.G2032R)
( ENST00000368507.8, ENST00000368508.7 ) 		Resitance or Non-Reponse true CIViC Evidence detail
Ba/F3 cells expressing the RANBP2-ALK fusion conta... ALK ALK p.Phe1174Leu (p.F1174L)
( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) ALK p.Phe1174Leu (p.F1174L)
( ENST00000618119.4, ENST00000642122.1, ENST00000389048.8 ) 		Resitance or Non-Reponse true CIViC Evidence detail
Ba/F3 cells expressing the EML4-ALK fusion contain... ALK ALK p.Phe1174Leu (p.F1174L)
( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) ALK p.Phe1174Leu (p.F1174L)
( ENST00000618119.4, ENST00000642122.1, ENST00000389048.8 ) 		Resitance or Non-Reponse true CIViC Evidence detail
High levels of crizotinib can overcome drug resist... ALK ALK p.Phe1174Leu (p.F1174L)
( ENST00000389048.8, ENST00000618119.4, ENST00000642122.1 ) ALK p.Phe1174Leu (p.F1174L)
( ENST00000618119.4, ENST00000642122.1, ENST00000389048.8 ) 		Sensitivity true CIViC Evidence detail
In a non-small cell lung cancer patient with an EG... EGFR EGFR p.Leu858Arg (p.L858R)
( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R)
( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) 		Resitance or Non-Reponse true CIViC Evidence detail
Amplification of wild-type EML4-ALK in the non-sma... ALK ALK EML4-ALK AMPLIFICATION Resitance or Non-Reponse true CIViC Evidence detail
The G1202R mutation in the EML4-ALK fusion was fou... ALK ALK p.Gly1202Arg (p.G1202R) ALK p.Gly1202Arg (p.G1202R) Resitance or Non-Reponse true CIViC Evidence detail
The L1196M mutation in the EML4-ALK fusion was fou... ALK ALK EML4-ALK L1196M Resitance or Non-Reponse true CIViC Evidence detail
The S1206Y mutation in the EML4-ALK fusion was fou... ALK ALK EML4-ALK S1206Y Resitance or Non-Reponse true CIViC Evidence detail
A lung adenocarcinoma patient responded to crizoti... ALK ALK EML4-ALK T1151INST Resitance or Non-Reponse true CIViC Evidence detail
In a never-smoking metastatic lung adenocarcinoma ... MET MET EXON 14 SKIPPING MUTATION MET EXON 14 SKIPPING MUTATION Sensitivity true CIViC Evidence detail
In a randomized, open-label phase 3 trial 303 pati... ALK ALK ALK FUSIONS ALK ALK FUSIONS Sensitivity true CIViC Evidence detail
A patient with anaplastic thyroid carcinoma harbor... ALK ALK ALK FUSIONS ALK ALK FUSIONS Sensitivity true CIViC Evidence detail
Patient was 34-year-old woman with vaginal sarcoma... ALK ALK ALK FUSIONS ALK ALK FUSIONS Sensitivity true CIViC Evidence detail
This is a case report of a 22-year-old Japanese m... ALK ALK ALK FUSIONS ALK ALK FUSIONS Sensitivity true CIViC Evidence detail
An expansion cohort of a phase-1 Crizotinib study ... ROS1 ROS1 REARRANGEMENT ROS1 REARRANGEMENT Sensitivity true CIViC Evidence detail
A case-study of an ALK-negative patient with MET a... MET MET AMPLIFICATION
( ENST00000318493.11 ) MET AMPLIFICATION
( ENST00000318493.11 ) 		Sensitivity true CIViC Evidence detail
The creation of a cell line model (HEK293) with ME... MET MET EXON 14 SKIPPING MUTATION MET EXON 14 SKIPPING MUTATION Sensitivity true CIViC Evidence detail
A patient with platinum-refractory oral cavity hea... MET MET R1004G MET R1004G Sensitivity true CIViC Evidence detail
Case-report of a patient with an acquired ALK L115... ALK ALK EML4-ALK L1152R Resitance or Non-Reponse true CIViC Evidence detail
11 patients with crizotinib-resistant NSCLC were a... ALK ALK EML4-ALK G1269A Resitance or Non-Reponse true CIViC Evidence detail
Pts with MET exon 14-altered NSCLC were enrolled i... MET MET EXON 14 SKIPPING MUTATION MET EXON 14 SKIPPING MUTATION Sensitivity true CIViC Evidence detail
In this case Report, a 67-year old female patient ... MET MET EXON 14 SKIPPING MUTATION MET EXON 14 SKIPPING MUTATION Sensitivity true CIViC Evidence detail
2 out of 7 patients with an acquired resistance to... ALK ALK EML4-ALK G1269A Resitance or Non-Reponse true CIViC Evidence detail
Two out of 11 patients with an acquired crizotinib... ALK ALK EML4-ALK AMPLIFICATION Resitance or Non-Reponse true CIViC Evidence detail
One patient with ALK-rearranged non-small cell lun... ALK ALK EML4-ALK AMPLIFICATION Resitance or Non-Reponse true CIViC Evidence detail
An 84 year old never-smoker with an upper chest ma... MET MET EXON 14 SKIPPING MUTATION MET EXON 14 SKIPPING MUTATION Sensitivity true CIViC Evidence detail
A cell line (DFCI076) with EML1-ALK fusion and res... AREG AREG EXPRESSION AREG EXPRESSION Resitance or Non-Reponse true CIViC Evidence detail
Five patients with acquired resistance to crizotin... AREG AREG EXPRESSION AREG EXPRESSION Resitance or Non-Reponse true CIViC Evidence detail
We now report responses to the MET inhibitors criz... MET MET EXON 14 SKIPPING MUTATION MET EXON 14 SKIPPING MUTATION Sensitivity true CIViC Evidence detail
Case report of a patient with MET amplification wi... MET MET AMPLIFICATION
( ENST00000318493.11 ) MET AMPLIFICATION
( ENST00000318493.11 ) 		Sensitivity true CIViC Evidence detail
In this case report, a patient with metastatic, AL... ALK ALK EML4-ALK C1156Y Resitance or Non-Reponse true CIViC Evidence detail
Case report of a patient with metastatic ALK-rearr... ALK ALK EML4-ALK C1156Y–L1198F Sensitivity true CIViC Evidence detail
Case report of a 73 year old patient with advanced... MET MET AMPLIFICATION
( ENST00000318493.11 ) MET AMPLIFICATION
( ENST00000318493.11 ) 		Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT04283669 Active, not recruiting Phase 2 Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas February 18, 2020 December 31, 2025
NCT06357975 Active, not recruiting Phase 2 Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) May 30, 2016 November 15, 2024
NCT04632758 Active, not recruiting Phase 3 Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients June 1, 2019 December 1, 2024
NCT02075840 Active, not recruiting Phase 3 A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants August 19, 2014 September 29, 2026
NCT03737994 Active, not recruiting Phase 2 Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer July 25, 2019 September 21, 2024
NCT04439266 Active, not recruiting Phase 2 Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F) August 12, 2015 February 28, 2025
NCT06360575 Active, not recruiting Phase 2 Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) May 30, 2016 November 15, 2024
NCT02465060 Active, not recruiting Phase 2 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) August 17, 2015 December 31, 2025
NCT03052608 Active, not recruiting Phase 3 A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC April 27, 2017 December 31, 2028
NCT02838420 Active, not recruiting Phase 3 A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) August 3, 2016 March 31, 2026
NCT02767804 Active, not recruiting Phase 3 eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients June 2016 December 31, 2025
NCT02761057 Active, not recruiting Phase 2 Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed July 25, 2016 December 12, 2024
NCT04439253 Active, not recruiting Phase 2 Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G) August 12, 2015 February 28, 2025
NCT02664935 Active, not recruiting Phase 2 National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer May 2015 September 2024
NCT01644773 Completed Phase 1 Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) November 27, 2012 September 28, 2018
NCT01712217 Completed Phase 1/Phase 2 A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib October 2012 May 16, 2017
NCT01744652 Completed Phase 1 Dasatinib and Crizotinib in Advanced Cancer March 2013 March 2019
NCT01945021 Completed Phase 2 Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC September 30, 2013 January 22, 2020
NCT01970865 Completed Phase 1/Phase 2 A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations January 8, 2014 May 24, 2023
NCT00828919 Completed N/A Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials March 7, 2003 August 14, 2023
NCT01998126 Completed Phase 1 Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer December 2, 2013 March 29, 2018
NCT01999972 Completed Phase 1 A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors February 26, 2014 September 5, 2019
NCT02034981 Completed Phase 2 Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1 August 2013 December 6, 2023
NCT02183870 Completed Phase 2 EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer May 2014 February 29, 2020
NCT02207504 Completed Phase 1 Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer August 2014 January 3, 2022
NCT02223819 Completed Phase 2 Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy March 2015 July 3, 2019
NCT02270034 Completed Phase 1 Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma August 13, 2014 October 26, 2020
NCT02419287 Completed Phase 2 Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas April 2015 December 2022
NCT02435108 Completed Phase 2 A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy May 15, 2014 July 15, 2016
NCT02574078 Completed Phase 1/Phase 2 A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) November 23, 2015 April 15, 2020
NCT01979536 Completed Phase 2 Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma November 13, 2013 March 31, 2024
NCT00939770 Completed Phase 1/Phase 2 Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma September 21, 2009 December 31, 2018
NCT01125904 Completed Phase 1 A Study To Investigate The Taste Of Crizotinib Liquid In Trained Healthy Adult Volunteers June 2010 June 2010
NCT01147055 Completed Phase 1 Estimation Of Effect Of Rifampin On Pharmacokinetics Of Crizotinib In Healthy Volunteers July 2010 October 2010
NCT01149785 Completed Phase 1 Estimation Of Effect Of Ketoconazole On Pharmacokinetics Of Crizotinib In Healthy Volunteers July 2010 September 2010
NCT01154218 Completed Phase 1 Bioequivalence And Food Effect Study Comparing The Commercial Formulation Of Crizotinib To Its Clinical Study Formulations And Commercial Formulation With Or Without Food In Healthy Volunteers August 2010 November 2010
NCT01168934 Completed Phase 1 A Phase 1 Absolute Bioavailability Study For Oral Crizotinib In Healthy Volunteers August 2010 September 2010
NCT01297595 Completed Phase 1 Relative Bioavailability Of A Crizotinib Oral Liquid Formulation To Crizotinib Formulated Capsule March 2011 April 2011
NCT01419041 Completed Phase 1 A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function November 2011 August 2012
NCT01531361 Completed Phase 1 Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations February 6, 2012 January 13, 2021
NCT01549574 Completed Phase 1 Drug Drug Interaction Study Of Crizotinib With Esomeprazole. May 2012 May 2012
NCT01576406 Completed Phase 1 Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients July 2012 June 2016
NCT01606878 Completed Phase 1 Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma April 29, 2013 December 31, 2018
NCT01639001 Completed Phase 3 A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients September 29, 2012 January 8, 2020
NCT02679170 Completed Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS) June 29, 2016 May 4, 2022
NCT02737501 Completed Phase 3 ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants May 26, 2016 January 29, 2021
NCT03088930 Completed Phase 2 Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer December 13, 2017 January 13, 2021
NCT03137134 Completed Phase 1 A Study to Evaluate the Effects of Food and Esomeprazole on the Pharmacokinetics of Crizotinib in a Coated Microsphere Formulation. June 20, 2017 October 17, 2017
NCT04647110 Completed Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers. December 14, 2020 March 15, 2021
NCT04856293 Completed Phase 1 Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS) April 16, 2021 December 15, 2021
NCT03085186 No longer available Treatment With Crizotinib Single Patient Expanded Access IND 134375
NCT02824094 No longer available Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC
NCT02473497 No longer available Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients
NCT05204628 Not yet recruiting Phase 3 A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib February 7, 2022 July 1, 2025
NCT02925234 Recruiting Phase 2 The Drug Rediscovery Protocol (DRUP Trial) August 2016 December 2027
NCT06082635 Recruiting Phase 3 TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC) December 14, 2023 November 30, 2028
NCT06140836 Recruiting Phase 3 A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) December 21, 2023 January 27, 2031
NCT03194893 Recruiting Phase 3 A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer July 5, 2017 June 12, 2026
NCT03297606 Recruiting Phase 2 Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) March 23, 2018 January 31, 2027
NCT03375242 Recruiting Safety and Efficacy of Xalkori ROS1 October 25, 2017 October 24, 2025
NCT03574402 Recruiting Phase 2 Phase II Umbrella Study Directed by Next Generation Sequencing July 9, 2018 December 30, 2024
NCT03646994 Recruiting Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer August 1, 2018 December 1, 2025
NCT03647111 Recruiting Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer January 1, 2018 December 1, 2025
NCT05725200 Recruiting Phase 2 Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer September 27, 2022 December 31, 2040
NCT05160922 Recruiting Phase 4 Crizotinib Continuation Clinical Study December 27, 2021 December 26, 2026
NCT03947385 Recruiting Phase 1/Phase 2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions June 28, 2019 May 31, 2025
NCT05014464 Recruiting ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma November 13, 2021 August 8, 2027
NCT04084717 Recruiting Phase 2 Study of Crizotinib for ROS1 and MET Activated Lung Cancer December 3, 2019 June 2025
NCT02201992 Recruiting Phase 3 Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) March 23, 2015 May 1, 2036
NCT04693468 Recruiting Phase 1 Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial December 1, 2020 September 3, 2025
NCT02194738 Recruiting N/A Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) September 26, 2014 September 28, 2026
NCT04322578 Recruiting Phase 2 Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC March 24, 2020 March 24, 2026
NCT05987332 Recruiting Phase 2/Phase 3 IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma October 31, 2023 January 15, 2028
NCT04603807 Recruiting Phase 3 A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases September 30, 2021 December 1, 2027
NCT05834348 Recruiting A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. June 26, 2023 February 3, 2025
NCT02511184 Terminated Phase 1 Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients October 2015 December 2017
NCT03672643 Terminated Phase 4 Long Term Safety Observation of Crizotinib in Chinese NSCLC Population January 28, 2019 September 28, 2023
NCT02134912 Terminated Phase 2 S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib August 2014 September 2016
NCT01822496 Terminated Phase 2 Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer November 4, 2013 June 4, 2018
NCT01121588 Terminated Phase 1 An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK) March 22, 2011 September 7, 2023
NCT02612194 Terminated Phase 2 LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer September 27, 2016 November 21, 2019
NCT02584634 Terminated Phase 1/Phase 2 Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) December 18, 2015 July 13, 2022
NCT04009317 Unknown status Phase 3 Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) August 13, 2019 April 30, 2022
NCT03874273 Unknown status Phase 2/Phase 3 Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors February 1, 2019 March 1, 2021
NCT02638428 Unknown status Phase 2 Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy December 2015 December 2023
NCT02499614 Unknown status Phase 2 Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS) December 2014 December 2018
NCT04292119 Unknown status Phase 1/Phase 2 Lorlatinib Combinations in Lung Cancer May 1, 2020 March 1, 2023
NCT03707847 Unknown status Phase 4 Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL October 1, 2018 February 1, 2021
NCT02836847 Unknown status Phase 2 Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma July 2016 December 2020
NCT02277457 Withdrawn Early Phase 1 Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations September 2015
NCT01500824 Withdrawn Phase 2 A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer May 2014 May 2016
NCT02487316 Withdrawn Phase 4 A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib July 2015 December 2017